This content is from: Home

Bayer hits back over Indian complusory licence ruling

German pharmaceutical company Bayer says it will appeal yesterday’s decision by India’s IP Appellate Board to uphold a compulsory licence granted over its cancer drug Nexavar

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | One Week Trial